RU2019130004A - Генная терапия при глазных заболеваниях - Google Patents
Генная терапия при глазных заболеваниях Download PDFInfo
- Publication number
- RU2019130004A RU2019130004A RU2019130004A RU2019130004A RU2019130004A RU 2019130004 A RU2019130004 A RU 2019130004A RU 2019130004 A RU2019130004 A RU 2019130004A RU 2019130004 A RU2019130004 A RU 2019130004A RU 2019130004 A RU2019130004 A RU 2019130004A
- Authority
- RU
- Russia
- Prior art keywords
- raav
- capsid
- associated virus
- recombinant adeno
- paragraphs
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 241000702421 Dependoparvovirus Species 0.000 claims 21
- 210000000234 capsid Anatomy 0.000 claims 14
- 239000000725 suspension Substances 0.000 claims 8
- 108091026890 Coding region Proteins 0.000 claims 6
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 241000701022 Cytomegalovirus Species 0.000 claims 3
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 claims 3
- 239000007900 aqueous suspension Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 230000004382 visual function Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 1
- 101001008411 Homo sapiens Lebercilin Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 102000052659 human LCA5 Human genes 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465649P | 2017-03-01 | 2017-03-01 | |
| US62/465,649 | 2017-03-01 | ||
| US201762469642P | 2017-03-10 | 2017-03-10 | |
| US62/469,642 | 2017-03-10 | ||
| PCT/US2018/020470 WO2018160849A1 (en) | 2017-03-01 | 2018-03-01 | Gene therapy for ocular disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019130004A true RU2019130004A (ru) | 2021-04-01 |
| RU2019130004A3 RU2019130004A3 (OSRAM) | 2021-07-05 |
Family
ID=63370488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019130004A RU2019130004A (ru) | 2017-03-01 | 2018-03-01 | Генная терапия при глазных заболеваниях |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11564996B2 (OSRAM) |
| EP (2) | EP4656244A2 (OSRAM) |
| JP (3) | JP7211960B2 (OSRAM) |
| KR (3) | KR20230093072A (OSRAM) |
| CN (2) | CN119752819A (OSRAM) |
| AU (2) | AU2018228881B2 (OSRAM) |
| BR (1) | BR112019017327A2 (OSRAM) |
| CA (1) | CA3054136A1 (OSRAM) |
| IL (2) | IL314284A (OSRAM) |
| RU (1) | RU2019130004A (OSRAM) |
| WO (1) | WO2018160849A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3103740A1 (en) * | 2018-06-29 | 2020-01-02 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| WO2021119544A1 (en) * | 2019-12-12 | 2021-06-17 | Novartis Ag | Injection device and injection solution transferring system |
| AU2022214429A1 (en) | 2021-02-01 | 2023-09-14 | Tern Therapeutics, Llc | Gene therapy for neuronal ceroid lipofuscinoses |
| US20220387627A1 (en) * | 2021-06-03 | 2022-12-08 | Hope for Hasti | Vectors and gene therapy for treating cornelia de lange syndrome |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
| US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| AU728220B2 (en) | 1997-04-14 | 2001-01-04 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant AAV product |
| WO1999061643A1 (en) | 1998-05-27 | 1999-12-02 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient |
| DE69941905D1 (de) | 1998-11-10 | 2010-02-25 | Univ North Carolina | Virusvektoren und verfahren für ihre herstellung und verabreichung. |
| JP4827353B2 (ja) | 1999-08-09 | 2011-11-30 | ターゲティッド ジェネティクス コーポレイション | 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大 |
| AU2001268149B2 (en) | 2000-06-01 | 2005-08-18 | University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
| CA2442670A1 (en) * | 2001-04-13 | 2002-10-24 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
| SG168422A1 (en) | 2001-11-13 | 2011-02-28 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| JP4810062B2 (ja) | 2001-12-17 | 2011-11-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | アデノ随伴ウイルス（ａａｖ）血清型８の配列 |
| US20070015238A1 (en) | 2002-06-05 | 2007-01-18 | Snyder Richard O | Production of pseudotyped recombinant AAV virions |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| EP1660970A4 (en) | 2003-08-01 | 2007-02-14 | Dna Twopointo Inc | SYSTEMS AND METHODS FOR BIOPOLYMER TECHNOLOGY |
| US8005620B2 (en) | 2003-08-01 | 2011-08-23 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
| EP3910063A1 (en) | 2003-09-30 | 2021-11-17 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| EP3409296A1 (en) | 2005-04-07 | 2018-12-05 | The Trustees of the University of Pennsylvania | Method of increasing the function of an aav vector |
| JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
| EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
| EP2091966A2 (en) * | 2006-12-01 | 2009-08-26 | Oxford BioMedica (UK) Limited | Promoter construct |
| WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| US20120172419A1 (en) * | 2009-09-15 | 2012-07-05 | Medical College Of Wisconsin Research Foundation Inc. | Reagents and methods for modulating cone photoreceptor activity |
| WO2011126808A2 (en) | 2010-03-29 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| US9249425B2 (en) * | 2011-05-16 | 2016-02-02 | The Trustees Of The University Of Pennslyvania | Proviral plasmids and production of recombinant adeno-associated virus |
| JP6184945B2 (ja) | 2011-06-08 | 2017-08-23 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法 |
| FR2977562B1 (fr) | 2011-07-06 | 2016-12-23 | Gaztransport Et Technigaz | Cuve etanche et thermiquement isolante integree dans une structure porteuse |
| CN104520428B (zh) * | 2012-02-17 | 2018-09-21 | 费城儿童医院 | 将基因转移到细胞、器官和组织的aav载体组合物和方法 |
| EP3800254A1 (en) | 2012-06-08 | 2021-04-07 | Ethris GmbH | Pulmonary delivery of messenger rna |
| JP6199965B2 (ja) | 2012-07-11 | 2017-09-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ｒｐｇｒｘ連鎖性網膜変性のａａｖ媒介型遺伝子治療 |
| CN104583457B (zh) | 2012-08-08 | 2016-09-28 | 日本帕卡濑精株式会社 | 金属表面处理液、金属基材的表面处理方法及由此而得的金属基材 |
| DK2954051T3 (da) | 2013-02-08 | 2019-07-08 | Univ Pennsylvania | Modificeret kapsid til genoverførsel til behandling af nethinden |
| US10369231B2 (en) * | 2013-03-11 | 2019-08-06 | Fondazione Telethon | MiR-204 and miR-211 and uses thereof |
| HK1220488A1 (zh) * | 2013-03-15 | 2017-05-05 | The Children's Hospital Of Philadelphia | 含有填充者/填充物多核苷酸序列的载体及其使用方法 |
| US9158889B2 (en) | 2013-04-26 | 2015-10-13 | Oral4D Systems Ltd. | Electronic dental charting |
| US9719106B2 (en) | 2013-04-29 | 2017-08-01 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof |
| WO2015009575A1 (en) * | 2013-07-16 | 2015-01-22 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of disorders related to cep290 |
| WO2016019364A1 (en) | 2014-08-01 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for self-regulated inducible gene expression |
-
2018
- 2018-03-01 KR KR1020237020037A patent/KR20230093072A/ko not_active Ceased
- 2018-03-01 KR KR1020197027823A patent/KR102545070B1/ko active Active
- 2018-03-01 AU AU2018228881A patent/AU2018228881B2/en active Active
- 2018-03-01 IL IL314284A patent/IL314284A/en unknown
- 2018-03-01 CA CA3054136A patent/CA3054136A1/en active Pending
- 2018-03-01 CN CN202411354454.9A patent/CN119752819A/zh active Pending
- 2018-03-01 CN CN201880029279.2A patent/CN110582572A/zh active Pending
- 2018-03-01 BR BR112019017327A patent/BR112019017327A2/pt not_active Application Discontinuation
- 2018-03-01 US US16/489,770 patent/US11564996B2/en active Active
- 2018-03-01 JP JP2019547457A patent/JP7211960B2/ja active Active
- 2018-03-01 EP EP25194444.3A patent/EP4656244A2/en active Pending
- 2018-03-01 KR KR1020247020928A patent/KR20240104196A/ko active Pending
- 2018-03-01 WO PCT/US2018/020470 patent/WO2018160849A1/en not_active Ceased
- 2018-03-01 EP EP18760861.7A patent/EP3589738A4/en active Pending
- 2018-03-01 RU RU2019130004A patent/RU2019130004A/ru unknown
-
2019
- 2019-08-27 IL IL26894619A patent/IL268946A/en unknown
-
2022
- 2022-12-05 US US18/061,633 patent/US20230233709A1/en active Pending
-
2023
- 2023-01-12 JP JP2023002799A patent/JP7671790B2/ja active Active
-
2024
- 2024-04-24 AU AU2024202693A patent/AU2024202693A1/en active Pending
-
2025
- 2025-04-18 JP JP2025068834A patent/JP2025114604A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024202693A1 (en) | 2024-05-16 |
| JP7671790B2 (ja) | 2025-05-02 |
| CN110582572A (zh) | 2019-12-17 |
| EP3589738A1 (en) | 2020-01-08 |
| US11564996B2 (en) | 2023-01-31 |
| WO2018160849A8 (en) | 2019-10-03 |
| KR102545070B1 (ko) | 2023-06-19 |
| JP7211960B2 (ja) | 2023-01-24 |
| US20190388561A1 (en) | 2019-12-26 |
| WO2018160849A1 (en) | 2018-09-07 |
| KR20240104196A (ko) | 2024-07-04 |
| IL314284A (en) | 2024-09-01 |
| CN119752819A (zh) | 2025-04-04 |
| EP3589738A4 (en) | 2021-01-06 |
| US20230233709A1 (en) | 2023-07-27 |
| BR112019017327A2 (pt) | 2020-04-14 |
| KR20230093072A (ko) | 2023-06-26 |
| JP2023040219A (ja) | 2023-03-22 |
| KR20190125357A (ko) | 2019-11-06 |
| AU2018228881B2 (en) | 2024-01-25 |
| IL268946A (en) | 2019-10-31 |
| EP4656244A2 (en) | 2025-12-03 |
| RU2019130004A3 (OSRAM) | 2021-07-05 |
| JP2025114604A (ja) | 2025-08-05 |
| CA3054136A1 (en) | 2018-09-07 |
| JP2020510433A (ja) | 2020-04-09 |
| AU2018228881A1 (en) | 2019-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021087431A5 (OSRAM) | ||
| US12257317B2 (en) | Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy | |
| Tal | Adeno-associated virus-based vectors in gene therapy | |
| US11344608B2 (en) | Factor IX gene therapy | |
| JP2021106619A5 (OSRAM) | ||
| JP7189771B2 (ja) | 筋ジストロフィーを治療するためのマイクロｒｎａ－２９およびマイクロジストロフィンのアデノ随伴ウイルスベクター送達 | |
| JP2021003120A5 (OSRAM) | ||
| JP2020528734A5 (OSRAM) | ||
| Stilwell et al. | Adeno-associated virus vectors for therapeutic gene transfer | |
| RU2017125234A (ru) | Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний | |
| RU2019130004A (ru) | Генная терапия при глазных заболеваниях | |
| JP2021500352A (ja) | 筋ジストロフィーを治療するための筋特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 | |
| RU2018125468A (ru) | Генная терапия офтальмологических нарушений | |
| JP2018510620A5 (OSRAM) | ||
| JP2020509786A5 (OSRAM) | ||
| JP2020510433A5 (OSRAM) | ||
| JP2018526994A5 (OSRAM) | ||
| Ortolano et al. | Present and future of adeno associated virus based gene therapy approaches | |
| Alexander et al. | Adeno-associated viral vectors and the retina | |
| US11821009B2 (en) | Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery | |
| WO2023111106A1 (en) | Fukutin related protein gene transfer increase using modified itr sequences | |
| Zhao et al. | Hot topics in adeno-associated virus as a gene transfer vector | |
| Okada | Efficient AAV vector production system: towards gene therapy for duchenne muscular dystrophy | |
| CA3146364A1 (en) | One-step gene therapy for duchenne muscular dystrophy via gene replacement and anti-inflammation | |
| Gray et al. | Vector design and considerations for CNS applications |